Reviewer ’s report  
 
Title: Hepatitis C -related cryoglobulinemic neuropathy: potential role of oxcarbazepine for pain  
control  
 
Version: 0 Date: 29 Dec 2017  
 
Reviewer: Theodoros Androutsakos  
 
Reviewer's report:  
 
Overall a good effort. However it needs to be revised as language is concerned (t.ex. it is not 
with sustained THE viral response, just sustained viral response) and I think you need to show us 
some more data about the HCV status of the patients included in this study (viral load and 
genotype). Moreover you are saying that 44 patients interrupted their treatment due to adverse 
effects. I would like to know what kind of adverse effects were these. 11 of your patients are said 
to have stopped treatment due to neuropathy ,so they should not be included in this study since 
your patients have HCV related and not interferon related neuropathy. Last but not least looks 
like 50% of your patients have also HBV infection ,unless what you mean is they had previous 
HBV infection, so I would like you to comment on that as well.  
 
 
 
 
Are the methods appropriate and well described?  
If not, please specify what is required in your comments to the authors.  
 
Yes 
 
Does the work include the necessary controls?  
If not, please specify which controls are required in your comments to the authors.  
 
Yes 
 
Are the conclusions drawn adequately supported by the data shown?  
If not, please explain in your comments to the authors.  
 
Yes 
 
Are you able to assess any statistics in the ma nuscript or would you recommend an  
additional statistical review?  
If an additional statistical review is recommended, please specify what aspects require further  
assessment in your comments to the editors.  
 
I am able to assess the statistics  
 
Quality of written English  
Please indicate the quality of language in the manuscript:  
 
Not suitable for publication unless extensively edited  
 
 
 
Declaration of competing interests  
Please complete a declaration of competing interests, considering the following qu estions:  
 
1. Have you in the past five years received reimbursements, fees, funding, or salary from an  
organisation that may in any way gain or lose financially from the publication of this  
manuscript, either now or in the future?  
 
2. Do you hold any stocks or shares in an organisation that may in any way gain or lose  
financially from the publication of this manuscript, either now or in the future?  
 
3. Do you hold or are you currently applying for any patents relating to the content of the  
manuscript?  
 
4. Have you received reimbursements, fees, funding, or salary from an organization that 
holds  or has applied for patents relating to the content of the manuscript?  
 
5. Do you have any other financial competing interests?  
 
6. Do you have any non -financial competing i nterests in relation to this paper?  
 
If you can answer no to all of the above, write 'I declare that I have no competing interests' 
below.  If your reply is yes to any, please give details below.  
 
I declare that I have no competing interes ts 
 
I agree to the ope n peer review policy of the journal. I understand that my name will be included  
on my report to the authors and, if the manuscript is accepted for publication, my named report  
including any attachments I upload will be posted on the website along with the authors'  
responses. I agree for my report to be made available under an Open Access Creative Commons  
CC-BY license ( http://creativecommons.org/licenses/by/4.0/ ). I understand that any comments  
which I do not wish to be included in my named report can be in cluded as confidential comments  
to the editors, which will not be published.  
 
I agree to the open peer review policy of the journal  
Reviewer ’s report  
 
Title: Hepatitis C -related cryoglobulinemic neuropathy: potential role of oxcarbazepine for pain  
control  
 
Version: 0 Date: 29 Dec 2017  
 
Reviewer: Theodoros Androutsakos  
 
Reviewer's report:  
 
Overall a good effort. However it needs to be revised as language is concerned (t.ex. it is not 
with sustained THE viral response, just sustained viral response) and I think you need to show us 
some more data about the HCV status of the patients included in this study (viral load and 
genotype). Moreover you are saying that 44 patients interrupted their treatment due to adverse 
effects. I would like to know what kind of adverse effects were these. 11 of your patients are said 
to have stopped treatment due to neuropathy ,so they should not be included in this study since 
your patients have HCV related and not interferon related neuropathy. Last but not least looks 
like 50% of your patients have also HBV infection ,unless what you mean is they had previous 
HBV infection, so I would like you to comment on that as well.  
 
 
 
 
Are the methods appropriate and well described?  
If not, please specify what is required in your comments to the authors.  
 
Yes 
 
Does the work include the necessary controls?  
If not, please specify which controls are required in your comments to the authors.  
 
Yes 
 
Are the conclusions drawn adequately supported by the data shown?  
If not, please explain in your comments to the authors.  
 
Yes 
 
Are you able to assess any statistics in the ma nuscript or would you recommend an  
additional statistical review?  
If an additional statistical review is recommended, please specify what aspects require further  
assessment in your comments to the editors.  
 
I am able to assess the statistics  
 
Quality of written English  
Please indicate the quality of language in the manuscript:  
 
Not suitable for publication unless extensively edited  
 
 
 
Declaration of competing interests  
Please complete a declaration of competing interests, considering the following qu estions:  
 
1. Have you in the past five years received reimbursements, fees, funding, or salary from an  
organisation that may in any way gain or lose financially from the publication of this  
manuscript, either now or in the future?  
 
2. Do you hold any stocks or shares in an organisation that may in any way gain or lose  
financially from the publication of this manuscript, either now or in the future?  
 
3. Do you hold or are you currently applying for any patents relating to the content of the  
manuscript?  
 
4. Have you received reimbursements, fees, funding, or salary from an organization that 
holds  or has applied for patents relating to the content of the manuscript?  
 
5. Do you have any other financial competing interests?  
 
6. Do you have any non -financial competing i nterests in relation to this paper?  
 
If you can answer no to all of the above, write 'I declare that I have no competing interests' 
below.  If your reply is yes to any, please give details below.  
 
I declare that I have no competing interes ts 
 
I agree to the ope n peer review policy of the journal. I understand that my name will be included  
on my report to the authors and, if the manuscript is accepted for publication, my named report  
including any attachments I upload will be posted on the website along with the authors'  
responses. I agree for my report to be made available under an Open Access Creative Commons  
CC-BY license ( http://creativecommons.org/licenses/by/4.0/ ). I understand that any comments  
which I do not wish to be included in my named report can be in cluded as confidential comments  
to the editors, which will not be published.  
 
I agree to the open peer review policy of the journal  
Please review this paper.
user
Reviewer ’s report  
 
Title: Hepatitis C -related cryoglobulinemic neuropathy: potential role of oxcarbazepine for pain  
control  
 
Version: 0 Date: 29 Dec 2017  
 
Reviewer: Theodoros Androutsakos  
 
Reviewer's report:  
 
Overall a good effort. However it needs to be revised as language is concerned (t.ex. it is not 
with sustained THE viral response, just sustained viral response) and I think you need to show us 
some more data about the HCV status of the patients included in this study (viral load and 
genotype). Moreover you are saying that 44 patients interrupted their treatment due to adverse 
effects. I would like to know what kind of adverse effects were these. 11 of your patients are said 
to have stopped treatment due to neuropathy ,so they should not be included in this study since 
your patients have HCV related and not interferon related neuropathy. Last but not least looks 
like 50% of your patients have also HBV infection ,unless what you mean is they had previous 
HBV infection, so I would like you to comment on that as well.  
 
 
 
 
Are the methods appropriate and well described?  
If not, please specify what is required in your comments to the authors.  
 
Yes 
 
Does the work include the necessary controls?  
If not, please specify which controls are required in your comments to the authors.  
 
Yes 
 
Are the conclusions drawn adequately supported by the data shown?  
If not, please explain in your comments to the authors.  
 
Yes 
 
Are you able to assess any statistics in the ma nuscript or would you recommend an  
additional statistical review?  
If an additional statistical review is recommended, please specify what aspects require further  
assessment in your comments to the editors.  
 
I am able to assess the statistics  
 
Quality of written English  
Please indicate the quality of language in the manuscript:  
 
Not suitable for publication unless extensively edited  
 
 
 
Declaration of competing interests  
Please complete a declaration of competing interests, considering the following qu estions:  
 
1. Have you in the past five years received reimbursements, fees, funding, or salary from an  
organisation that may in any way gain or lose financially from the publication of this  
manuscript, either now or in the future?  
 
2. Do you hold any stocks or shares in an organisation that may in any way gain or lose  
financially from the publication of this manuscript, either now or in the future?  
 
3. Do you hold or are you currently applying for any patents relating to the content of the  
manuscript?  
 
4. Have you received reimbursements, fees, funding, or salary from an organization that 
holds  or has applied for patents relating to the content of the manuscript?  
 
5. Do you have any other financial competing interests?  
 
6. Do you have any non -financial competing i nterests in relation to this paper?  
 
If you can answer no to all of the above, write 'I declare that I have no competing interests' 
below.  If your reply is yes to any, please give details below.  
 
I declare that I have no competing interes ts 
 
I agree to the ope n peer review policy of the journal. I understand that my name will be included  
on my report to the authors and, if the manuscript is accepted for publication, my named report  
including any attachments I upload will be posted on the website along with the authors'  
responses. I agree for my report to be made available under an Open Access Creative Commons  
CC-BY license ( http://creativecommons.org/licenses/by/4.0/ ). I understand that any comments  
which I do not wish to be included in my named report can be in cluded as confidential comments  
to the editors, which will not be published.  
 
I agree to the open peer review policy of the journal  
assistant